Busulfan and thiotepa conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma

被引：0

作者：

Jung, Sung-Hoon ^{[1
]}

Ahn, Seo-Yeon ^{[1
]}

Yang, Deok-Hwan ^{[1
]}

Kim, Hyeoung-Joon ^{[1
]}

Kim, Jin Seok ^{[2
]}

Kim, Kihyun ^{[3
]}

Eom, Hyeon-Seok ^{[4
]}

Yhim, Ho-Young ^{[5
]}

Lee, Yoo Jin ^{[6
]}

Hyun, Shin Young ^{[7
]}

Lee, Je-Jung ^{[1
]}

机构：

[1] Chonnam Natl Univ, Hwasun Hosp, Hwasun Gun, South Korea

[2] Yonsei Univ, Coll Med, Severance Hosp, Seoul, South Korea

[3] Samsung Med Ctr, Seoul, South Korea

[4] Natl Canc Ctr, Goyang Si, South Korea

[5] Chonbuk Natl Univ, Sch Med, Jeonju, South Korea

[6] Kyungpook Natl Univ Hosp, Daegu, South Korea

[7] Wonju Severance Christian Hosp, Wonju, South Korea

来源：

BONE MARROW TRANSPLANTATION | 2019年 / 54卷

关键词：

D O I：

暂无

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

P129

引用

下载

页码：226 / 226

页数：1

共 50 条

[1] Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
Song, Ga-Young
Jung, Sung-Hoon
Kim, Mihee
Ahn, Seo-Yeon
Ahn, Jae-Sook
Yang, Deok-Hwan
Kim, Hyeong-Joon
Kim, Jin Seok
Eom, Hyeon-Seok
Moon, Joon Ho
Yhim, Ho-Young
Kim, Kihyun
Min, Chang-Ki
Lee, Je-Jung
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S157 - S158
[2] Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study)
Song, Ga-Young
Jung, Sung-Hoon
Kim, Jin Seok
Eom, Hyeon Seok
Moon, Joon Ho
Yhim, Ho-Young
Kim, Kihyun
Min, Chang-Ki
Lee, Je-Jung
FRONTIERS IN ONCOLOGY, 2022, 12
[3] Application of the Conditioning Regimen with Busulfan and Cyclophosphamide in Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
Xu, Yun
Yao, Ying
Yao, Weiqin
Jin, Song
Yan, Lingzhi
Shang, Jingjing
Fu, Chengcheng
Wu, Depei
BLOOD, 2017, 130
[4] Intravenous busulfan with thiotepa and cyclophosphamide (TBC) as a conditioning regimen for autologous progenitor cell transplantation (PCT) in patients with multiple myeloma (MM).
Anagnostopoulos, A
Aleman, A
Weber, D
Andersson, B
Braunschweig, I
Claxton, D
Donato, M
Khouri, I
Anderlini, P
Korbling, M
Gajewski, J
Alexanian, R
Champlin, R
Giralt, S
BLOOD, 1999, 94 (10) : 335A - 335A
[5] APPLICATION OF CONDITIONING REGIMEN WITH BUSULFAN AND CYCLOPHOSPHAMIDE IN AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
Xu, Y.
Fu, C.
Yao, Y.
Yao, W.
Jin, S.
Yan, L.
Shang, J.
Zhu, X.
Sun, A.
Wu, D.
HAEMATOLOGICA, 2017, 102 : 787 - 787
[6] Thiotepa and melphalan as a new conditioning regimen for autologous transplantation in multiple myeloma
Grimaldi, F.
Madonna, E.
Avilia, S.
Pane, F.
Risitano, A. M.
De Rosa, G.
BONE MARROW TRANSPLANTATION, 2013, 48 : S209 - S209
[7] Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma
Cogle, CR
Moreb, JS
Leather, HL
Finiewicz, KJ
Khan, SA
Reddy, VS
Wingard, JR
AMERICAN JOURNAL OF HEMATOLOGY, 2003, 73 (03) : 169 - 175
[8] Busulfan,cyclophosphamide and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma
张春阳
China Medical Abstracts (Internal Medicine), 2013, 30 (02) : 116 - 117
[9] Single daily dose of intravenous busulfan and melphalan as conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation
de la Rubia, J.
Lahuerta, J.
Gonzalez, J.
Solano, C.
Rivas, P.
BONE MARROW TRANSPLANTATION, 2007, 39 : S323 - S323
[10] Busulfan and melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
Jung, Sung-Hoon
Lee, Je-Jung
Kim, Jin Seok
Min, Chang-Ki
Kim, Kihyun
Choi, Yunsuk
Eom, Hyeon-Seok
Joo, Young Don
Kim, Sung-Hyun
Kwak, Jae-Yong
Kang, Hye Jin
Lee, Jae Hoon
Lee, Ho Sup
Mun, Yeung-Chul
Moon, Joon Ho
Sohn, Sang Kyun
Park, Seong Kyu
Park, Yong
Shin, Ho-Jin
Yoon, Sung-Soo
BONE MARROW TRANSPLANTATION, 2018, 53 : 262 - 263

← 1 2 3 4 5 →